LCI News and Press, Lannett Co Inc From 03/29/22

LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE PR Newswire --First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa. ...

Lannett (NYSE:LCI) received another notice from the NYSE dated Mar. 14, notifying that it is not in compliance with continued listing standards as the average closing price of its stock was less than $1/share over 30 straight trading days. LCI has 6 months from the date of the notice to regai...

LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE PR Newswire TREVOSE, Pa. , March 18, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The electric vehicle (EV) market faces a real test in 2022 due to ongoing subsidy cuts by the Chinese government. Nio’s (NYSE: NIO ) deliveries in January and February have slowed considerably as a result. I...

LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14 --Company Announces Receipt of FDA Complete Response Letter (CRL) for Generic Advair Diskus® Product; Based on Preliminary Review, Company Expects At Least a Second Review Cycle-- PR Newswire TR...

Lannett Company (NYSE:LCI) receives NYSE motice dated March 2, 2022, saying that it is not in compliance because its average market capitalization has been less than $50M over a consecutive 30 trading-day period, and at the same time its last reported stockholders' equity was below $50M....

LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE PR Newswire TREVOSE, Pa. , March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated Mar...

Lannett (NYSE:LCI) has agreed to sell its liquid drug manufacturing facility in Carmel, New York and other assets to a private company for $10.5M in cash. The transaction is anticipated to close within the next several weeks and is expected to stream line streamlining Lannett's manufacturing ...

LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million --Transaction a Key Element of Company's Plan to Streamline Operations and Reduce Costs; Proceeds Further Strengthens Cash Position-- PR Newswire PHILADELPHIA , March 4...

Lannett finds itself at a confluence of choices brought forth more by management than the macro-environment. With revenues sinking to new lows, investors are left wondering if management can find a path to the aspirational goal of $1 billion in revenues by 2025. With a share price...